- Policy
- Will the COVID-19 drug Paxlovid be reimbursed in H1 2024?
- by Lee, Tak-Sun Apr 16, 2024 05:46am
- Whether the reimbursement of the COVID-19 drug Paxlovid (nirmatrelvir and ritonavir, Pfizer), which the government has been working to make part of Korea’s general healthcare system after the end of the COVID-19 pandemic, will be able to be listed within the originally planned date is gaining attention. The Korea Disease Control and Prev
- Policy
- Drugs with 'amlodipine' formulation get pediatric indication
- by Lee, Hye-Kyung Apr 15, 2024 06:06am
- Now, the 109 items of 'amlodipine besylate' monotherapy, which is used for the treatment of hypertension and angina, can be used for treating pediatric patients with hypertension. The Ministry of Food and Drug Safety (MFDS) ordered the change of approval conditions for 'amlodipine besylate monotherapy (doses 5mg, 10mg, tab)'. The change of a
- Company
- Pharma, Biotech had outstanding export performance last year
- by Kim, Jin-Gu Apr 15, 2024 06:06am
- It is reported that 30 of the listed pharmaceutical and biotechnology companies achieved a year-over-year (YoY) growth of 18% in export performance. Samsung Biologics’ exports significantly increased from KRW 2.85 trillion in 2022 to KRW 3.58 trillion last year. SK Biopharmaceuticals, ST Pharm, and Hanmi Pharmaceutical also experienced
- Company
- Samsung Bioepis’s Stelara biosimilar Epyztek is approved
- by Son, Hyung-Min Apr 15, 2024 06:06am
- Samsung Bioepis announced on the 11th that it has obtained the first biosimilar approval in Korea for its autoimmune disease treatment Stelara biosimilar, Epyztek (project name SB17), from the Ministry of Food and Drug Safety. Stelara, which was developed by global pharmaceutical giant Janssen, is used to treat plaque psoriasis, psoria
- Company
- Interleukin inhibitors approved for palmoplantar pustulosis
- by Eo, Yun-Ho Apr 15, 2024 06:06am
- Interleukin (IL)-23 inhibitors, which are mainly used for psoriasis, are making their way into the field of palmoplantar pustulosis in Korea. Following the approval of Janssen Korea’s ‘Tremfya (guselkumab), AbbVie Korea’s Skyrizi (risankizumab) has also added an indication for palmoplantar pustulosis and has signaled competition in the
- InterView
- 'BMS will invest in and improve access to new drugs in KOR'
- by Eo, Yun-Ho Apr 15, 2024 06:06am
- Multinational pharmaceutical companies are masters of adaptation and transformation. They adjust their pipelines and introduce new drugs through various mergers and acquisitions and technology export agreements to meet the rapidly changing trends in the healthcare industry. This involves a great deal of foresight. The companies need to as
- Company
- MSD Korea’s sales 7%↓ due to the transfer of Januvia sales
- by Son, Hyung-Min Apr 15, 2024 06:05am
- The sales of MSD Korea last year declined by 7.3% year-over-year (YoY). The sales of cancer immunotherapy 'Keytruda' have increased significantly, while the sales of COVID-19 treatment 'Lagevrio' have decreased. The company’s external growth appears to have stalled. Moreover, the transfer of local sales rights of a diabetes drug 'Januvia' se
- Company
- Boryung actively pursues co-promotion deals…
- by Kim, Jin-Gu Apr 12, 2024 05:41am
- Boryung proactively seeks opportunities to partner with pharmaceutical and biotechnology companies in South Korea and overseas. Boryung appears to be in full swing after signing a co-distribution agreement with HK inno.N for 'K-CAB' and the four items of 'Kanarb' series at the end of last year. Pharmaceutical industry experts antici
- Product
- ‘Wholesale inventory of 110 antitumor drugs at its lowest'
- by Kang, Hye-Kyung Apr 12, 2024 05:41am
- The Korean Pharmacists for Democratic Society (President: Kyung-Lim Jeon, KPDS) has pointed out the issue of antineoplastic drugs being out of stock. In the second week of April, the KPDS revealed through the ‘Stock Shortage Drugs of the Week Report’ that an estimated wholesale stock of 110 antineoplastic drugs has run out. The 110 ite
- Company
- ‘Mounjaro may shift the Type 2 diabetes treatment paradigm'
- by Son, Hyung-Min Apr 12, 2024 05:41am
- Mounjaro has shown the most potent effect among incretin-based therapeutic agents. Based on the dramatic effect it showed in reducing blood sugar levels and weight loss in clinical trials, we expect the drug will bring about many changes field of diabetes treatment.” Thomas Forst, Professor of Internal Medicine and Endocrinology at the
